Facebook
Twitter
LinkedIn
ForwardClinical Trials in Personalized Medicine in Oncology
Session Description
Personalized medicine in oncology is the application of genomic and proteomic data to tailor a specific therapy to the patient’s cancer. With the advent of rapid sequencing, mutational analysis has revealed potentially actionable targets that may provide a more effective and potentially less toxic treatment for malignancies. Conventional chemotherapy continues to be the backbone of therapy; novel therapeutics have been developed to exploit these genetic flaws. In breast, lung, melanoma, and gastrointestinal cancers, the implementation of combination and targeted agents has resulted in a renewed interest in applying these principles in the adjuvant and neoadjuvant space. This session will cover the emerging data from clinical trials across solid tumor types. Attendees will understand tumor genomic sequencing, potential targets, and agents under investigation.
Moderator: Flavio G. Rocha, MD, FACS, Seattle, WA
Co-Moderator: Christina L. Roland, MD, MS, FACS, Houston, TX
Presentations
Introduction to Personalized Oncology
Flavio G. Rocha, MD, FACS, Seattle, WA
Christina L. Roland, MD, MS, FACS, Houston, TX
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I PREDICT)
Jason K. Sicklick, MD, FACS, La Jolla, CA
Is There a Role for Precision Medicine for Patients with Pancreatic Cancer?
Susan Tsai, MD, MHS, FACS, Milwaukee, WI
Personalized Medicine in Thoracic Surgical Oncology Trials
Dennis A. Wigle, MD, PhD, FACS, Rochester, MN
Molecular Targets in Advanced Colorectal Cancer
Flavio G. Rocha, MD, FACS, Seattle, WA
Sponsored by the ACS Clinical Research Program Education Committee and the Scientific Forum Committee
Target Audience
- Practicing surgeons
- Residents
Learning Objectives
- Apply new knowledge and ideas to improve their surgical practice
- Adapt concepts and quality measures in support of research advancements
- Enhance the quality of patient care
Contact
For questions about the course, please contact elearning@facs.org.
Disclosure Information
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all relevant financial relationships with any commercial interest. For additional information, please visit the ACCME website.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the educational activity. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during a activity, please report it on the evaluation.
(Download the full list of disclosures).
Faculty and Disclosures
Charlotte E. Ariyan, MD, PhD, FACS - Pfizer Stock: Spouse is employee:
Christina L. Roland, MD, MS, FACS - Bristol Myers Squibb: Research Funding: Principal Investigator
Dennis A. Wigle MD, PhD, FACS - Nothing to Disclose
Flavio G. Rocha MD, FACS - Nothing to Disclose
Jason K. Sicklick, MD, FACS - Amgen: Research Funding: PI; Novartis Pharmaceuticals: Research Funding: PI; CARsgen Therapeutics Corporation: Honoraria: Consultant; Foundation Medicine, Inc: Research Funding: PI; Grand Rounds: Honoraria: Consultant; Loxo Oncology: Honoraria: Consultant
John H. Stewart, MD, MBA, FACS - Amgen: Research Grant: Study Chair
Rebecca Ann C. Auer, MD, FRCSC, FACS - ATGen Inc: PI; Enhanced Medical Nutrition Inc.: PI; Leo Pharma Inc.: PI; Vaxinia Inc.: Advisory Board Member
Susan Tsai MD, MHS FACS - Nothing to Disclose
Program Committee and Disclosures
CHAIR: Henri R. Ford, MD, MHA, FACS, FAAP, FRCSEng(Hon), Miami, FL - Nothing to Disclosure
VICE-CHAIR: David T. Cooke, MD, FACS, Sacramento, CA - Nothing to Disclosure
Members
David C. Borgstrom, MD, FACS, Morgantown, WV - Nothing to Disclosure
Daniel L. Dent, MD, FACS, San Antonio, TX - Nothing to Disclosure
Roger R. Dmochowski, MD, FACS, Nashville, TN - Allergen: Honoraria: Consultant
Cynthia D. Downard, MD, FACS, Louisville, KY - Nothing to Disclosure
Audra A. Duncan, MD, FACS, London, ON - Nothing to Disclosure
Mariam F. Eskander, MD, Boston, MA - Nothing to Disclosure
Paula Ferrada, MD, FACS, Richmond, VA - Nothing to Disclosure
Neil H. Hyman, MD, FACS, Chicago, IL - Nothing to Disclosure
Martin S. Karpeh, Jr., MD, FACS, New York, NY - Nothing to Disclosure
Dennis H. Kraus, MD, FACS, New York, NY - Nothing to Disclosure
Kenneth W. Sharp, MD, FACS, Nashville, TN - Nothing to Disclosure
Ex-Officios
Daniel M. Herron, MD, FACS, FASBMS, New York, NY - Nothing to Disclosure
Edith Tzeng, MD, FACS, Pittsburgh, PA - Nothing to Disclosure
Consultants
Barbara Lee Bass, MD, FACS, FRCSEng(Hon), FRCSI(Hon), FCOSECSA(Hon), Houston, TX - Nothing to Disclosure
Quan-Yang Duh, MD, FACS, San Francisco, CA - Nothing to Disclosure
B. J. Hancock, MD, FACS, FRCSC, Winnipeg, MB - Nothing to Disclosure
Ronald V. Maier, MD, FACS, FRCSEd(Hon), Seattle, WA - Nothing to Disclosure
Continuing Medical Education Credit Information
Accreditation
The American College of Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA PRA Category 1 Credits™
The American College of Surgeons designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, a maximum of 1.5 credits meets the requirements for Self-Assessment.
Note: Residents will receive a Certificate of Completion.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Certificate of Completion
- 1.50 Self Assessment Credit
This course is available as part of the Clinical Congress 2019 Webcast Packages